Granite Investment Partners, LLC Otonomy, Inc. Transaction History

Granite Investment Partners, LLC

  • $2.32 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 01, 2018
SELL
$2.8 - $5.55 $100,377 - $198,961
-35,849 Closed
0 $0
Q3 2017

Nov 08, 2017
BUY
$3.2 - $20.8 $114,716 - $745,659
35,849
35,849 $117,000

About OTONOMY, INC.

OTIC Quotes by TradingView
  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track Granite Investment Partners, LLC Portfolio

Follow Granite Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granite Investment Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email